Abbvie humira patent cliff status 2024?

Short answer: By 2024, Humira’s patent protection in the U.S. was effectively past its main expiry, and biosimilar competition had become substantial. AbbVie faced growing competition from adalimumab biosimilars (marketed by several manufacturers) and has been shifting strategy toward newer AbbVie products to offset Humira’s revenue decline.

A bit more context you might find helpful:
- What “patent cliff” means here: The key adalimumab (Humira) patents covering composition and major uses expired in the early-to-mid 2020s in the U.S., which opened the U.S. market to biosimilars. Several biosimilars were on the market or launched around 2023–2024.
- U.S. market: Biosimilars of Humira have competed for patient access since 2023–2024. Amjevita (adalimumab-atto) and Cyltezo (adalimumab-adbm) are examples of U.S. biosimilars that contributed to competition; there are additional entrants and ongoing patent-related proceedings that can affect launch timelines for specific indications or formulations.
- Global view: Europe and other regions saw earlier access to Humira biosimilars in many markets, with competition ramping up across 2018–2024.
- AbbVie’s response: Revenue from Humira has come under pressure due to biosimilars, and AbbVie has been expanding and promoting other products (notably Skyrizi and Rinvoq) to offset declines from Humira.

If you’d like, I can:
- Provide a region-by-region timeline of key patent expiries and major biosimilar launches.
- List the main biosimilar entrants and approximate launch dates.
- Include sources for regulatory dates and market launches.

Tell me which region or level of detail you want (U.S. focus, EU focus, or global), and I’ll pull a concise timeline with dates.